MediciNova, Inc. (NASDAQ:MNOV) – Research analysts at Zacks Investment Research issued their Q1 2019 earnings per share (EPS) estimates for MediciNova in a report released on Wednesday, February 20th. Zacks Investment Research analyst D. Bautz forecasts that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. Zacks Investment Research also issued estimates for MediciNova’s Q2 2019 earnings at ($0.14) EPS, Q3 2019 earnings at ($0.15) EPS and Q4 2019 earnings at ($0.15) EPS.
Separately, BidaskClub raised shares of MediciNova from a “sell” rating to a “hold” rating in a research report on Thursday, November 8th.
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in MediciNova by 10.3% in the 2nd quarter. BlackRock Inc. now owns 2,375,416 shares of the biopharmaceutical company’s stock worth $18,909,000 after acquiring an additional 222,277 shares in the last quarter. California Public Employees Retirement System grew its stake in MediciNova by 52.1% in the 2nd quarter. California Public Employees Retirement System now owns 64,798 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 22,198 shares in the last quarter. Northern Trust Corp grew its stake in MediciNova by 9.3% in the 2nd quarter. Northern Trust Corp now owns 455,130 shares of the biopharmaceutical company’s stock worth $3,623,000 after acquiring an additional 38,551 shares in the last quarter. Alps Advisors Inc. grew its stake in MediciNova by 24.2% in the 3rd quarter. Alps Advisors Inc. now owns 74,109 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 14,423 shares in the last quarter. Finally, Alliancebernstein L.P. bought a new position in shares of MediciNova during the third quarter valued at approximately $132,000. 22.10% of the stock is owned by hedge funds and other institutional investors.
MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.